Manchester Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Manchester Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-540	Closed	-$9.33K	–	1443
2025 Q3	$9.33K	Hold	540	–	–	﹤0.01%	879
2025 Q2	$5.07K	Hold	540	–	–	﹤0.01%	902
2025 Q1	$3.84K	Hold	540	–	–	﹤0.01%	934
2024 Q4	$6.3K	Hold	540	–	–	﹤0.01%	865
2024 Q3	$11.1K	Hold	540	–	–	﹤0.01%	776
2024 Q2	$12.1K	Buy	+540	New	+$12.9K	﹤0.01%	729
2023 Q4	–	Sell	-2,000	Closed	-$63.2K	–	1053
2023 Q3	$63.2K	Hold	2,000	–	–	0.01%	391
2023 Q2	$81.6K	Hold	2,000	–	–	0.01%	370
2023 Q1	$74.5K	Hold	2,000	–	–	0.01%	383
2022 Q4	$69.8K	Hold	2,000	–	–	0.01%	355
2022 Q3	$112K	Hold	2,000	–	–	0.02%	272
2022 Q2	$104K	Hold	2,000	–	–	0.02%	296
2022 Q1	$145K	Sell	2,000 -104	-5%	-$8.81K	0.02%	286
2021 Q4	$249K	Hold	2,104	–	–	0.03%	239
2021 Q3	$282K	Buy	+2,104	New	+$319K	0.04%	242

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Manchester Capital Management's NTLA Position: Q4 2025 in Review

Manchester Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 540 shares — an estimated $9.33K sold.

Manchester Capital Management first reported a position in NTLA in Q3 2021 and held it in 15 quarters. The position peaked at $282K in Q3 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

Manchester Capital Management reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
Manchester Capital Management sold 540 Intellia Therapeutics shares in Q4 2025, an estimated $9.33K.
Manchester Capital Management first reported a position in Intellia Therapeutics in Q3 2021 and held it in 15 quarters.
Manchester Capital Management's Intellia Therapeutics position peaked at $282K in Q3 2021.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Manchester Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.